Drug-class evidence
Survodutide (investigational) clinical trials
1 pivotal trial of survodutide (investigational), spanning Survodutide (investigational). 387 total participants across the published evidence base.
What we know about survodutide (investigational)
Survodutide (BI 456906) is an investigational once-weekly dual glucagon/GLP-1 receptor agonist — it is NOT FDA-approved. Its Phase 2 obesity trial reported up to ~18.7% mean weight loss at 46 weeks; it is also being studied in MASH (metabolic dysfunction-associated steatohepatitis).
Percent weight loss across Survodutide (investigational) obesity trials
Primary-endpoint percent body-weight change for the published survodutide (investigational) weight-management trials. Conducted on FDA-approved branded products only.
| Trial | NCT ID | Percent weight loss |
|---|---|---|
| Survodutide Phase 2 (obesity) · Survodutide (investigational) | NCT04667377 | 18.7% |
Effect sizes across survodutide (investigational) trials
| Trial | Brand | Indication | Weight loss | A1C reduction | N · year |
|---|---|---|---|---|---|
| Survodutide Phase 2 (obesity) | Survodutide (investigational) | Obesity / overweight | 18.7% | — | 387 · 2024 |
All survodutide (investigational) trials
Trials cited are for the FDA-approved branded products containing survodutide (investigational). Compounded versions have not been studied in equivalent randomized controlled trials. GLP1Zoom does not provide medical advice; discuss treatment with your prescribing clinician. Full disclaimer.